Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Cipla
Medtronic
Fuji
QuintilesIMS
Federal Trade Commission

Generated: August 25, 2019

DrugPatentWatch Database Preview

Claims for Patent: 10,309,921

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,309,921
Title:Label-free electrochemical biosensor
Abstract: The current invention pertains to electrochemical biosensors. The electrochemical biosensor of the current invention comprises: a) a sensing electrode having attached to its surface a binding agent capable of specifically binding to the analyte to form a binding agent-analyte complex and wherein the binding of the analyte to the binding agent alters the electron transfer properties at the sensing electrode surface thereby providing a change in the electrochemical response at the sensing electrode surface proportional to the number of binding agent-analyte complexes, and b) a test equipment capable of measuring the electrochemical response at the sensing electrode surface. The binding agent can be a binding protein, an antibody, or an aptamer, and the analyte can be a biomolecule. Accordingly, the current invention provides a method of detecting the presence or assessing the likelihood of development of a disease associated with an abnormal level of a biomolecule in a subject.
Inventor(s): Bhansali; Shekhar (Weston, FL), Mallari; Abhay Vasudev (Hillsboro, OR)
Assignee: THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (Miami, FL)
Application Number:14/636,758
Patent Claims:1. An electrochemical biosensor for measuring concentration of an analyte in a fluid, the electrochemical biosensor comprising: a) a sensing electrode having deposited onto its surface a polyaniline (PANI)-silver-silver oxide core-shell (Ag@AgO) nanocomposite that immobilizes a binding agent capable of specifically binding to the analyte to form a binding agent-analyte complex and wherein the binding of the analyte to the binding agent causes electron transfer resistance at the sensing electrode surface thereby providing a change in the electrochemical response at the sensing electrode surface proportional to the number of binding agent-analyte complexes, b) a detection solution comprising a soluble redox probe, and c) a test equipment capable of measuring the electrochemical response at the sensing electrode surface.

2. The electrochemical biosensor of claim 1, wherein the sensing electrode is fabricated from a noble metal.

3. The electrochemical biosensor of claim 2, wherein the noble metal is copper, silver, platinum, gold, bismuth, palladium, osmium, iridium, ruthenium, and rhodium.

4. The electrochemical biosensor of claim 1, wherein the binding agent is a binding protein, an antibody, or an aptamer that specifically binds to the analyte and the analyte is a biomolecule.

5. The electrochemical biosensor of claim 4, wherein the biomolecule is a hormone, a protein, a polysaccharide, a lipid, a polynucleotide, or a metabolite.

6. The electrochemical biosensor of claim 5, wherein the hormone is a peptide hormone or a steroid hormone.

7. The electrochemical biosensor of claim 6, wherein the peptide hormone is selected from Thyroid-stimulating hormone (TSH), Follicle-stimulating hormone (FSH), Luteinizing hormone (LH), Prolactin (PRL), Growth hormone (GH), Adrenocorticotropic hormone (ACTH), Vasopressin, Oxytocin, Thyrotropin-releasing hormone (TRH), Gonadotropin-releasing hormone (GnRH), Growth hormone-releasing hormone (GHRH), Corticotropin-releasing hormone (CRH), Somatostatin, Calcitonin, Parathyroid hormone (PTH), FGF-23 (phosphatonin), Osteocalcin, Erythropoietin (EPO), Human chorionic gonadotropin (HCG), Insulin, Glucagon, Amylin, Atrial-natriuretic peptide (ANP), Gastrin, Secretin, Cholecystokinin (CCK), Fibroblast Growth Factor 19 (FGF19), Neuropeptide Y, Ghrelin, PYY3-36, Insulin-like growth factor-1 (IGF-1), Angiotensinogen, Thrombopoietin, Hepcidin, Betatrophin, Leptin, Retinol Binding Protein 4, Adiponectin, and Irisin.

8. The electrochemical biosensor of claim 6, wherein the steroid hormone is selected from progesterone, aldosterone, testosterone, estradiol, and cortisol.

9. The electrochemical biosensor of claim 1, wherein the soluble redox probe is ferro-ferri cyanide.

10. A method of measuring concentration of an analyte in a fluid, the method comprising: a) providing an electrochemical biosensor comprising: A) a sensing electrode having deposited onto its surface a polyaniline (PANI)-silver-silver oxide core-shell (Ag@AgO) nanocomposite that immobilizes a binding agent capable of specifically binding to the analyte form a binding agent-analyte complex and wherein the binding of the analyte to the binding agent causes electron transfer resistance at the sensing electrode surface thereby providing a change in the electrochemical response at the sensing electrode surface proportional to the number of binding agent-analyte complexes, B) a detection solution comprising a soluble redox probe, and C) a test equipment which measures the electrochemical response at the sensing electrode surface, b) contacting the sensing electrode with the fluid under conditions that allow the formation of the binding agent-analyte complexes for a period of time sufficient to allow the formation of the binding agent-analyte complexes, c) washing the sensing electrode with a washing solution to remove unbound and non-specifically bound chemicals from the sensing electrode, d) introducing a detection solution over the sensing electrode, e) measuring the electrochemical response at the sensing electrode surface, and f) calculating the concentration of the analyte in the fluid based on the electrochemical response at the sensing electrode surface.

11. The method of claim 10, wherein the binding agent is a binding protein, an antibody, or an aptamer that specifically binds to the analyte and the analyte is a biomolecule.

12. The method of claim 11, wherein the biomolecule is a protein, a hormone, or a metabolite.

13. The method of claim 12, wherein the hormone is a peptide hormone or a steroid hormone.

14. The method of claim 13, wherein the peptide hormone is selected from TSH, FSH, LH, PRL, GH, ACTH, Vasopressin, Oxytocin, TRH, GnRH, GHRH, CRH, Somatostatin, Calcitonin, PTH, FGF-23, Osteocalcin, EPO, HCG, Insulin, Glucagon, Amylin, ANP, Gastrin, Secretin, CCK, FGF19, Neuropeptide Y, Ghrelin, PYY3-36, IGF-1, Angiotensinogen, Thrombopoietin, Hepcidin, Betatrophin, Leptin, Retinol Binding Protein 4, Adiponectin, and Irisin.

15. The method of claim 13, wherein the steroid hormone is selected from progesterone, aldosterone, testosterone, estradiol, and cortisol.

16. The method of claim 10, wherein the soluble redox probe is ferro-ferri cyanide.

17. A method of detecting the presence of a cortisol-related chronic condition in a subject, the method comprising: a) providing an electrochemical biosensor comprising: A) a sensing electrode having attached to its surface a binding agent capable of specifically binding to cortisol to form a binding agent-cortisol complex and wherein the binding of cortisol to the binding agent causes electron transfer resistance at the sensing electrode surface thereby providing a change in the electrochemical response at the sensing electrode surface proportional to the number of binding agent-cortisol complexes, B) a detection solution comprising a soluble redox probe, and C) a test equipment which measures the electrochemical response at the sensing electrode surface, b) contacting the sensing electrode with the biofluid under conditions that allow the formation of the binding agent-cortisol complexes for a period of time sufficient to allow the formation of the binding agent-cortisol complexes, c) washing the sensing electrode with a washing solution to remove unbound and non-specifically bound chemicals from the sensing electrode, d) introducing a detection solution over the sensing electrode, e) measuring the electrochemical response at the sensing electrode surface, f) calculating the concentration of cortisol in the biofluid based on the electrochemical response at the sensing electrode surface, and g) identifying the subject as having a cortisol-related chronic condition; if the concentration of cortisol in the biofluid is higher or lower than the concentration of cortisol in the biofluid of a subject not having the cortisol-related chronic condition, wherein the biofluid of the subject and the subject not having the cortisol-related chronic condition are collected at similar times of day.

18. The method of claim 17, wherein the binding agent is a binding protein, an antibody, or an aptamer that specifically binds to cortisol.

19. The method of claim 17, wherein the soluble redox probe is ferro-ferri cyanide.

Details for Patent 10,309,921

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 001 2015-01-23   Try a Free Trial THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (Miami, FL) 2034-03-03 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 002 2015-01-23   Try a Free Trial THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (Miami, FL) 2034-03-03 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 003 2015-01-23   Try a Free Trial THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (Miami, FL) 2034-03-03 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
AstraZeneca
Cipla
Citi
Chinese Patent Office
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.